Capecitabine

Evidence Level: L5

Predicted Indications: 1

Capecitabine

Pharmacist Assessment Report

Capecitabine: From Gastric Cancer to Gastric Adenocarcinoma and Proximal Polyposis of the Stomach

One-Sentence Summary

Capecitabine is an oral fluoropyrimidine chemotherapy. The TxGNN model predicts it may be useful for gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS), but the data compiled for this report contain no clinical trials and no publications on this condition, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Gastric cancer and metastasis from malignant tumour of colon (relations recorded in the knowledge graph; the Australian licence record contains no indication text)
Predicted New Indication	Gastric adenocarcinoma and proximal polyposis of the stomach
TxGNN Prediction Score	0.9994
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, capecitabine is a prodrug converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA and RNA synthesis. This general knowledge is not drawn from the supplied data.

GAPPS is a rare hereditary syndrome associated with APC promoter 1B mutations. No syndrome-specific evidence was supplied, so whether capecitabine’s mechanism applies to this setting is unverified.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 8362D	Capecitabine Sandoz	Tablet 500 mg	Not stated in the licence record

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (fluoropyrimidine class)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions. The knowledge graph lists neutropenia, thrombocytopenia, agranulocytosis and anaemia as contraindication relations.
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the PI. Based on the graph-recorded relations, full blood count, liver function and renal function are relevant.
Handling Protection	Follow local cytotoxic drug handling requirements

Safety Considerations

Contraindication relations in the knowledge graph (not label text): liver disease, gallbladder disease, thrombocytopenia, infectious disease, neutropenia, agranulocytosis, coronary artery disease, anaemia, macrocytic anaemia, hyperbilirubinaemia, hereditary hyperbilirubinaemia, Gilbert syndrome, impaired renal function, sudden cardiac arrest, heart conduction disease, necrotizing enterocolitis, stomatitis, and dihydropyrimidine dehydrogenase deficiency.
Drug interactions: 100 interactions were found in the interaction query. The main ones listed are:
- Moderate: metronidazole, tinidazole
- Minor: aluminium hydroxide, levofloxacin, magaldrate, magnesium carbonate, magnesium hydroxide, magnesium oxide
- Level unknown: pantoprazole, omeprazole, lansoprazole, glimepiride, doxycycline, morphine, metformin, atropine, prednisone, simvastatin, hydrocortisone, dolasetron
Only the first 20 are shown in the data compiled for this report.

Warnings and contraindications from the TGA-approved Product Information were not available. Please refer to the PI for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high, but it comes from the TxGNN model (deep learning) only. There are no trials or publications on GAPPS, and the score may reflect similarities the model learned between related diseases, not biological evidence. Evidence level is L5.

To proceed, the following is needed:

Syndrome-specific clinical or observational evidence in GAPPS
Mechanism of action data
TGA Product Information, including indications, warnings and contraindications
A review of DPD deficiency testing and other safety considerations for this hereditary population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.